

# Medications for Diabetes and Its Complications: A Case-Based Approach

CHAMPS Webcast, January 16, 2008

Presented by Laura Shane-McWhorter, PharmD

Evaluation & CME Questions



Name, credentials: \_\_\_\_\_

Title: \_\_\_\_\_

Organization: \_\_\_\_\_

Address/City/State: \_\_\_\_\_

E-mail Address: \_\_\_\_\_

Phone Number: \_\_\_\_\_

This contact information is **required** if you would like to receive a Certificate of Participation or CE Credit for this webcast.

***Fax your completed form to Andrea Martin at CHAMPS, (303) 861-5315. Questions? Call (303) 861-5165 x285.***

**Please complete the following evaluation questions (pages 1-3) so we can review our goals, objectives, and topics for future webcasts. Participants interested in receiving continuing education credit must also complete the CE questions following the evaluation questions (page 4).**

**If you complete the Evaluation Questions and provide your contact information, you will receive a certificate of participation for this event. If you complete the CE questions and provide contact information, you will receive either a continuing medical education certificate for 1.5 credits or a statement of credit for 1.5 contact hours of pharmacy CE within six weeks.**

## **EVALUATION QUESTIONS**

### **1) Please rate your overall satisfaction with this webcast:**

- Very Satisfied
- Satisfied
- Neither Satisfied nor Dissatisfied
- Dissatisfied
- Very Dissatisfied

### **2) I feel this presentation addressed Educational Objective #1: *Describe the current controversy surrounding glitazone use***

- Strongly Agree
- Agree
- Neither Agree nor Disagree
- Disagree
- Strongly Disagree

### **3) I feel this presentation addressed Educational Objective #2: *Describe use of newer agents for diabetes including inhaled insulin and DPP-IV inhibitors***

- Strongly Agree
- Agree
- Neither Agree nor Disagree
- Disagree
- Strongly Disagree

**4) I feel this presentation addressed Educational Objective #3:** *List new American Heart Association target blood pressures for specific disease states*

- Strongly Agree
- Agree
- Neither Agree nor Disagree
- Disagree
- Strongly Disagree

**5) I feel this presentation addressed Educational Objective #4:** *Review information regarding the direct renin inhibitor, aliskiren*

- Strongly Agree
- Agree
- Neither Agree nor Disagree
- Disagree
- Strongly Disagree

**6) I feel this presentation addressed Educational Objective #5:** *Discuss priorities in hyperlipidemia treatment in patients with diabetes*

- Strongly Agree
- Agree
- Neither Agree nor Disagree
- Disagree
- Strongly Disagree

**7) Rate your experience registering, logging on, and participating in this webcast through your computer system:**

- Very Easy
- Easy
- Neither Easy nor Difficult
- Difficult
- Very Difficult

**8) The speaker was knowledgeable on the topic:**

- Strongly Agree
- Agree
- Neither Agree nor Disagree
- Disagree
- Strongly Disagree

**9) The content was presented in a scientifically balanced manner:**

- Strongly Agree
- Agree
- Neither Agree nor Disagree
- Disagree
- Strongly Disagree

**10) The educational materials (slides or handouts, case studies, learning activities) promoted my understanding of the material:**

- Strongly Agree
- Agree
- Neither Agree nor Disagree
- Disagree
- Strongly Disagree

**11) The speaker was interesting to listen to:**

- Strongly Agree
- Agree
- Neither Agree nor Disagree
- Disagree
- Strongly Disagree

**12) The speaker fostered active participation in learning:**

- Strongly Agree
- Agree
- Neither Agree nor Disagree
- Disagree
- Strongly Disagree

**13) This webcast gave me practical tools I can use while working:**

- Strongly Agree
- Agree
- Neither Agree nor Disagree
- Disagree
- Strongly Disagree

**14) How likely are you to attend another CHAMPS webcast?**

- Very Likely
- Likely
- Somewhat Likely
- Not Very Likely
- Not at All Likely

**15) Briefly describe the best aspects of this webcast:**

**16) Please describe how this webcast could be improved:**

**17) List other training topics that would meet the needs of your job:**

**18) Other Comments:**

***Thank you for your responses. If you are not applying for CE credit, please fax these responses to Andrea Martin at CHAMPS, (303) 861-5315. Otherwise, continue to the CE Credit questions on page 4.***

**CONTINUING EDUCATION (CE) CREDIT QUESTIONS**

You may earn 1.5 hours of continuing medical education (CME) credit or 1.5 contact hours of continuing pharmacy education credit for this event\*. Please indicate the type of credit you are applying for:

- Continuing Medical Education (CME) credit  
 Continuing Pharmacy Education credit

You must attend the entire webcast and complete the following post-test in order to qualify for either type of CE credit. Failure to complete all CE questions will result in no CE credit awarded.

19) The number of persons with diabetes who have A1C, blood pressure, and cholesterol controlled is 25%.

- True  
 False

20) Which of the following is true?

- A) Glitazones may be associated with increased fractures in the hip and spine in women  
 B) Glitazones may be associated with increased fractures in the arm, hand, and foot in women  
 C) Glitazones may be associated with decreased fractures in males  
 D) Glitazones may be responsible for causing increased fractures in males

21) In the new American Heart Association guidelines, beta blockers may not be first line agents.

- True  
 False

22) In a person with diabetes who has an A1C of 6.5%, total cholesterol is 198 mg/dL, LDL is 100 mg/dL, triglycerides are 500 mg/dL, and HDL is 28 mg/dL, which of the following is true?

- A) The main priority is treating the LDL, so no treatment is necessary  
 B) The main priority is to treat a low HDL, so start niacin  
 C) The main priority is to treat the elevated triglycerides, so start a triglyceride lowering agent  
 D) The main priority is to treat the diabetes and since A1C is at goal, no treatment is necessary

\*Continuing Medical Education credit approved by the American Academy of Family Physicians (AAFP).



The University of Colorado Denver School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been accredited 1.5 contact hours and assigned the ACPE numbers: 008-999-08-004-L01-P (live webcast) and 008-999-08-004-H01-P (archived webcast). To receive CE credit, participants must complete the evaluation and post-questions. CE credit will issued within 6 weeks. Initial release 1-16-2008; archived webcast expires 1-16-2009.

***Thank you for applying for Continuing Education Credit.  
Please fax your responses to Andrea Martin at CHAMPS, (303) 861-5315.***